Boots on the ground

Ben Wu


Mr. Wu is currently the Healthcare Director at Agio Capital, a Belgium based advisory firm.  Agio Capital provides financial & business advisory services to support mainly Europeans healthcare pharma, biotech and medical technology companies towards China.  Agio’s main activities include facilitating European licensing and technology transfer to Chinese biotech and pharma companies, direct entry of European companies into China for commercialization, formation of joint ventures with Chinese companies and search for Chinese investors and strategic partners. More recently, Agio has also been active in helping Chinese biotechs to partner in Europe.

Mr. Wu has a deep knowledge in the pharmaceutical markets and a strong network with the venture capital community in the Greater China region.

Mr. Wu has close to thirty years of experience in the pharmaceutical industry, holding senior executive positions in the Asia Pacific region.  Mr. Wu first joined Sanofi-Genzyme in 2008 to pioneer the company’s efforts in expanding into Hong Kong, followed by general management positions covering Southeast Asia, Taiwan and China.  Mr. Wu was the general manager at Sanofi-Genzyme in China from 2012-2015. Prior to joining Genzyme, Mr. Wu spent over 14 years at Johnson & Johnson where he held local and regional leadership positions.

More recently, Mr. Wu was the founding CEO of Citrine Medicine from 2019 to 2021.  Citrine Medicine was founded in 2019 as a China-based, unmet need driven rare disease therapeutic platform built on strong co-development and scalable commercialization capabilities.

Prior to joining Citrine Medicine, Mr. Wu was the Head of Rare Diseases at CANbridge Pharmaceuticals from 2017-2019.  At CANbridge, Mr. Wu established the company’s first rare disease business unit.  CANbridge Pharmaceuticals (HKEX:1228) became the first rare disease focused company to be listed on the Hong Kong Stock Exchange.

Mr. Wu is a registered pharmacist in Canada, with a bachelor’s degree in Pharmaceutical Sciences and an MBA from the University of British Columbia in Canada.